Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 472 shares of the firm's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the transaction, the insider now owns 17,331 shares in the company, valued at $512,650.98. The trade was a 2.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Irene Becklund also recently made the following trade(s):
- On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.42, for a total transaction of $9,166.24.
Hims & Hers Health Stock Performance
Hims & Hers Health stock opened at $31.12 on Wednesday. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of 70.73 and a beta of 1.25. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02. The firm has a 50 day moving average price of $25.27 and a two-hundred day moving average price of $21.14.
2025’s #1 Trump Trade
From The Oxford Club | Ad
All the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can.
Three Companies Set to See Enormous Profit Potential.
Details Here.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the business earned ($0.04) earnings per share. Hims & Hers Health's revenue for the quarter was up 77.1% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.
Institutional Investors Weigh In On Hims & Hers Health
Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 67.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company's stock valued at $13,701,000 after acquiring an additional 273,473 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company's stock valued at $10,095,000 after acquiring an additional 320,000 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Hims & Hers Health by 322.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company's stock worth $1,056,000 after acquiring an additional 39,943 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Hims & Hers Health by 33.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,830 shares of the company's stock worth $562,000 after purchasing an additional 6,912 shares during the period. Institutional investors own 63.52% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on HIMS. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. TD Cowen restated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday. They set an "overweight" rating and a $42.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $22.80.
Get Our Latest Stock Analysis on Hims & Hers Health
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
